StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

Research analysts at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, February 12th.

Aptose Biosciences Trading Up 7.6 %

APTO stock opened at $0.19 on Monday. The company has a market cap of $11.65 million, a price-to-earnings ratio of -0.07 and a beta of 0.88. The firm has a 50-day moving average of $0.21 and a two-hundred day moving average of $0.31. Aptose Biosciences has a 12 month low of $0.13 and a 12 month high of $2.01.

Aptose Biosciences shares are going to reverse split on Wednesday, February 26th. The 1-30 reverse split was announced on Tuesday, February 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, February 25th.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Bleichroeder LP acquired a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned 4.15% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is owned by hedge funds and other institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.